Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1745-1750

  Lorenz, Katrin ^a   Rosbach, Klaus ^b   Matt, Andreas ^b   Pfeiffer, Norbert ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

Adjunctive therapy; Brinzolamide; Carbonic anhydrase inhibitor; Fixed combination; Glaucoma; Intraocular pressure

Indexed keywords

BIMATOPROST; BRINZOLAMIDE PLUS TIMOLOL; LATANOPROST; TAFLUPROST; TRAVOPROST;

ADULT; ADVERSE DRUG REACTION; AGED; ANXIETY; ARTICLE; BITTER TASTE; BLURRED VISION; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY EYE; EYE BURNING; FEMALE; GASTROINTESTINAL DISEASE; GLUED EYE; HELICOBACTER INFECTION; HUMAN; INTRAOCULAR HYPERTENSION; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84856161720     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S25987     Document Type: Article

References (16)

1. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. Savona, Italy: Dogma; 2008.
2. Travatan [package insert]. Fort Worth, TX: Alcon Laboratories Inc; 2004.
3. Xalatan [package insert]. New York, NY: Pfizer Inc; 2009.
4. Lumigan [package insert]. Irvine, CA: Allergan Inc; 2010.
5. Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009;19: 66-71.
6. Feuerhake C, Buchholz P, Kimmich F. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Curr Med Res Opin. 2009;25:1037-1043.
7. Azarga. Summary of product characteristics. Chicago, IL: Alcon Pharma; 2008.
8. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115: 1728-1734.
9. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18:293-300.
10. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2008;24: 601-605.
11. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009;116:1719-1724.
12. Cheng JW, Li Y, Wei RL. Systematic review of intraocular pressurelowering effects of adjunctive medications added to latanoprost. Ophthalmic Res. 2009;42:99-105.
13. Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009;25:1645-1653.
14. Azopt [package insert]. Fort Worth, TX: Alcon Laboratories Inc; 2008.
15. Timolol maleate ophthalmic solution USP [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2004.
16. Andrade S. Compliance in the real world. Value Health. 1998;1: 171-173.